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Introduction. To evaluate whether secondary resection of lymph node (LN) metastases (LNMs) can result in PSA remission,
we analysed the PSA outcome after resection of LNM detected on PET/CT in patients with biochemical failure. Materials and
Methods. 11 patients with PSA relapse (mean 3.02ng/mL, range 0.5–9.55ng/mL) after radical prostatectomy without adjuvant
therapywere included. Suspicious LN(1–3) detected oncholine PET/CTand nearbyLNwere openly dissected (09/04–02/11).The
PSA development was examined. Histological and PET/CT ﬁndings were compared. Results. 9 of 10 patients with histologically
conﬁrmed LNM showed a PSA response. 4 of 9 patients with single LNM had a complete permanent PSA remission (mean
followup 31.8, range 1–48 months). Of metastasis-suspicious LNs (14) 12 could be histologically conﬁrmed. The additionally
removed 25 LNs were all correctly negative. Conclusions. The complete PSA remissions after secondary resection of single LNM
argue for a feasible therapeutic beneﬁt without adjuvant therapy. For this purpose the choline PET/CT is in spite of its limitations
currently the most reliable routinely available diagnostic tool.
1.Introduction
In prostate cancer the long relapse-free survival of patients
with 1-2 LNM even without adjuvant therapy in the primary
situation [1, 2] argues for a feasible therapeutic beneﬁt by
resection of LNM especially in case of minimal lymphatic
dissemination. To evaluate whether the sole secondary
resection of LNM can result in a prostate-speciﬁc antigen
(PSA)remission,weanalysedthePSAoutcomeaftertargeted
resection of LNM detected via choline positron emission
tomography (PET)/computed tomography (CT) in patients
with biochemical failure after radical retropubic prostatec-
tomy.
In our ﬁrst studies of PET/CT-guided secondary LN
surgery, we reported on the outcome of all in all 8
patients with LNM detected by using [11C]choline PET/CT
without adjuvant therapy [3, 4]. 3 of 6 patients with single
LN recurrence showed a complete PSA remission without
adjuvanttherapyupto32months.Nowwewantedtoupdate
the results of secondary LN dissection in consideration
of more patients and a longer followup. Moreover, in
our present study patients with LNM detected by using
[18F]ﬂuoroethylcholine were included too.
Former studies of others could give no evidence for PSA-
remissionafterthesolesecondaryresectionofLNM,whereas
a resection of LNM was followed by adjuvant therapy [5, 6]
and patients without adjuvant therapy were monitored for
only a short time, respectively [7].
The integrated [11C]choline and [18F]ﬂuoroethylcholine
PET/CT provides the opportunity to detect small LNM
(>5mm) in prostate cancer with exact topographic alloca-
tion and so the targeted resection of LNM. In contrast, the2 Advances in Urology
computed tomography (CT) and the conventional magnetic
resonance imaging (MRI) are not applicable for early
detection of LN recurrence. The lymphotropic nanoparticle-
enhanced MRI can detect smaller LNM (>2mm) [8] but has
not been approved for routine diagnostics.
2.MaterialsandMethods
2.1. Patients. 11 consecutive patients (mean age 62 years,
range 49–78 years) with 1–3 LNM detected by using
[11C]choline PET/CT (n = 9) or [18F]ﬂuoroethylcholine
PET/CT (n = 2) in case of PSA failure (mean 3.02ng/mL,
range 0.5–9.55ng/mL) were included. All had a PSA increase
or persistence after operative therapy which was performed
between 3 months and 9 years ago. In 10 patients a radical
retropubic prostatectomy with pelvic LN dissection (PLND)
and in one patient only a radical retropubic prostatectomy
were carried out. One patient had received a sentinel guided
PLND (sPLND) on both sides of the pelvic and also an
extended PLND (ePLND) on the right side because of an
advanced tumor and another one only sPLND in our clinic.
The remaining patients had received conventional PLND,
carried out by other institutions. There had to be negative
margins and no clue for a local relapse or distant metastasis.
The patients were informed that there is no conclusive data
concerning survival beneﬁt after secondary LN surgery in
written and oral form, and signed an informed consent.
2.2. Choline PET/CT Imaging. All [11C]choline or [18F]ﬂuo-
roethylcholine PET/CT studies were performed with inte-
grated PET/CT systems externally in four centres with a
high level of expertise. Experienced radiologists and nuclear
medicine specialists evaluated the images to anatomically
localize the sites of pathologic choline uptake. The diagnosis
of tumor positive LN on PET/CT images was based on the
visual evidence of the presence of focal increased choline
uptake on PET images, whose location corresponded to LN
on CT images (Figure 1).
2.3. Surgical Procedure, PSA Development, and Histologi-
cal Evaluation. The LN/LNM detected by use of choline
PET/CT and the nearby LN were openly dissected by
two high-volume surgeons (09/2004–02/2011). The PSA
development was monitored up to 48 months (mean 18.6,
range 1–48 months) postoperatively. The primary histolog-
ical diagnosis was made on hematoxylin and eosin-stained
sections. Immunohistochemical staining of cytokeratins was
performed to verify micrometastases. In one case, additional
antibodies against PSA, prostate speciﬁc acid phosphatase,
p504s, and the proliferation marker Ki67 were employed for
typing of the metastatic tissue. The histological ﬁndings were
compared with the PET/CT results.
3. Results
A summary of the patient characteristics is shown in Table 1.
The mean PSA value at the date of the choline-PET/CT
examination was 3.02ng/mL (range 0.5–9.55ng/mL).
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Figure 1: Integrated [11C]choline PET/CT shows a single LNM in
the right iliac region. The LNM was conﬁrmed histopathologically
after secondary resection. (Source: Clinic of Nuclear Medicine
and Institute of Clinical Radiology, University Hospital Muenster,
Germany).
In 10 of 11 patients the metastasis-suspicious LN de-
tected by means of PET/CT could be completely removed.
They were also histologically positive. In one patient with
two metastasis-suspicious LN detected on PET/CT, only one
histological negative LN could be resected because of severe
cicatrization. A further 25 (mean 2.3, range 0–10) adjacent
PET/CT negative LNs were dissected and negative for cancer.
Inonecase,neighbouringLNcouldnotberemoved,because
only three months ago this patient received a sPLND and
ePLND on the concerning side in our clinic. In another
patient only cicatricial tissue could be removed in addition
to one LNM after radiotherapy. In the same patient a small
lesionoftheureternecessitatedasecondaryureteralstenting.
In all other cases the intra- and postoperative courses were
without complications.
After the secondary LN resection, 9 of 10 patients with
histologically conﬁrmed LNM showed a PSA response. 4
of 9 patients with single metastases had a lasting complete
PSA remission (<0.01ng/mL (n = 3), <0.03ng/mL (n =
1)) without adjuvant therapy. The maximum followup of
these patients was 48 months (mean 31.8 months, range 1–
48 months). The other 5 patients with single LNM initially
showed a PSA remission, 4 of them a partial incomplete
remission. In one of these cases, a local recurrence was
detected in the course of the study by means of PET/CT
and MRI. In two other patients with incomplete remission
already a tumorous inﬁltration of the adjacent tissue was his-
tologically detected. In the patient without PSA response, 3
LNMs were histologically conﬁrmed. The PSA development
of all patients can be seen in Table 2 and Figure 2.Advances in Urology 3
Table 1: Summary of the patient characteristics.
Patient Age (yr) Primary
treatment
Initial tumour
stage
Gleason
score
Hormonal
therapy
after
primary
treatment
Radiotherapy
after primary
treatment
PSA
initial
(ng/mL)
PSA1
(ng/mL)
PET/CT
positive LN
1 61 RPE + PLND pT3a pN0 cM0
R0 3+4 −− 4.13 0.92 1
2 59 RPE + PLND pT2c pN0 cM0
R0 4+3 + − 26.7 4.09 1
36 4 RPE + Splnd +
ePLND right
pT3a pN1 cM0
R0 4+3 −− 16.0 2.45 1
46 8 R P E pT3a pN0 cM0
R0 ? − + 9.9 1.64 1
5 78 RPE + PLND pT3b pN0 cM0
R0 3+4 −− 3.2 1.62 1
6 59 RPE + PLND pT3a pN0 cM0
R0 4+3 + − 7.6 4.51 1
7 49 RPE + PLND pT3b pN0 cM0
R0 4+5 −− 4.0 0.67 1
8 61 RRP + PLND pT3a pN0 cM0
R0 5 + 5 + + ? 9.55 3
9 53 RRP + PLND pT3a pN0 cM0
R1 4+4 − + 36.0 3.54 1
10 75 RRP + sPLND pT3a pN0 cM0
R1 4+3 − + 5.94 3.77 1
11 55 RRP + PLND pT3b pN1 cM0
R0 4+3 −− 5.08 0.5 2
mean 62 3.02
PSA initial: PSA at primary diagnosis; PSA1: PSA at time of PET/CT diagnosis.
Table 2: PSA development after secondary resection of LNM
without adjuvant therapy.
Patient PSA1
(ng/mL)
PSA2
(ng/mL)
Follow up
(month)
10 . 9 2 <0.03 48
24 . 0 9 <0.01 48
32 . 4 5 <0.01 30
41 . 4 6 <0.01 1
5 1.62 2.7 27
6 4.51 1.5 6
7 0.67 0.03 5
8 9.55 54.46 12
9 3.54 0.4 7
10 3.77 (6.51∗) 10.3 2
11 No LNM histologically conﬁrmed
PSA1: PSA at time of PET/CT diagnosis; PSA2: PSA after resection of LNM;
∗preoperative, 3 months after PET/CT.
4. Discussion
The studies dealing with the secondary resection of LNM
existing so far could give no evidence concerning the PSA
response. The patients were either treated postoperatively
with hormones or radiation [5, 6] or were monitored
without adjuvant therapy for a maximum of four months,
respectively [7]. In our present study 4 patients with single
LNM even showed a complete and lasting PSA remission,
over a maximum followup of 48 months, without an
adjuvant treatment. These results conﬁrm our previous data
of the complete PSA remission in patients with single LN
recurrence after secondary LN dissection [4].
Whether patients can beneﬁt therapeutically by the
removal of LNM in prostate cancer is still inconclusive.
In our group the complete PSA remissions after secondary
resection of single LNM argue for a feasible therapeutic
beneﬁt. Nevertheless, the small number of cases and the
comparative short followup is a limitation of our study. The
long-term outcome of patients undergoing PET/CT guided
secondary resection of LNM remains to be seen. However,
observations in the primary situation support a therapeutic
beneﬁt especially for patients with minimal lymphatic dis-
semination. Several reports suggest that ePLND increases the
likelihood of ﬁnding positive nodes and improves biochem-
ical relapse free survival [1, 9]. In the study of Daneshmand
et al. [1] LN-positive patients had a progression-free survival
of 70% (one positive LN), respectively, 73% (two positive
LNs) after ten years. von Bodman et al. showed [2] that the
time (median) to relapse without adjuvant therapy was 59
months (1 LNM), 13 months (2 LNMs), and 3 months for4 Advances in Urology
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Figure 2: PSA development after secondary resection of LNM
without adjuvant therapy.
patients with 3 LNMs. After 24 months 79% (one positive
LN, Gleason-Score ≤7) or 29% (≥two positive LN, Gleason-
Score ≥8) were free of biochemical relapse. Catalona et al.
[10] reported that LN-positive patients without an adjuvant
treatment developed no biochemical recurrence in 75% over
six years and up to 58% over seven years. A population-
based case-cohort study indicates a possible therapeutic
beneﬁt of PLND in node negative patients [11]. However,
several studies demonstrated that in histologically negative
LN tumor cells could be detected by real-time reverse
transcriptase PCR [12, 13].
A limitation of secondary LN surgery in PCa is the lim-
ited sensitivity of the currently available imaging, especially
in detection of small LNM. Contrary to conventional MRI
andCT,thePET([11C]choline,[11F]choline)oﬀerskeybene-
ﬁts in detecting LNM in the primary and recurrent diagnosis
o fP C af o c io fs i z e su pt o5m m[ 14, 15]. Nonetheless, the
value of this method is limited because of the frequency of
smallermetastases(<5mm)[16,17].Otherauthorshavealso
shown the method’s inaccuracy in detecting lesions smaller
than 1cm [18–20], but CT and MRI are far more unre-
liable in these cases [21]. The lymphotropic nanoparticle-
enhanced MRI can detect smaller LNM (>2mm) [8]b u t
has not been approved for routine diagnostics. In the
future, the diﬀusion-weighted MRI could provide additional
information on tumor pathophysiology compared to the
standardized uptake values (SUV) in choline PET/CT. In
a pilot study of Beer et al., [22] the apparent diﬀusion
coeﬃcient value in diﬀusion-weighted MRI and the SUV in
PET showed a highly signiﬁcant inverse correlation in LN
diagnostics.
Whether choline PET/CT oﬀers the basis of early treat-
ment decisions in patients with PSA failure after radical
prostatectomy is a subject of ongoing discussion. Picchio et
al. suggest that the routine use of choline PET/CT cannot
be recommended for PSA values <1ng/mL[23]. However,
patients with local recurrence after radical prostatectomy are
best treated by salvage radiotherapy when the PSA serum
level is <0.5ng/mL. We could detect positive ﬁndings with
a very low PSA value (≥0.67ng/mL). Also Scattoni et al. [5]
and others [24, 25] have shown positive results in patients
withverylowPSAlevels(<1ng/mL).InastudyofCastellucci
et al. it was possible to detect recurrent disease in 28% of
patients with PSA <1.5ng/mL by PET/CT [26]. In 21% of
the patients distant unexpected metastases were detected by
PET/CT. In those cases an unnecessary local radiotherapy
can be avoided.
Our study shows a complete correlation between
[11C]choline PET/CT as well as [18F]ﬂuoroethylcholine
PET/CT and histological ﬁndings in patients with single
LNM (speciﬁcity 100%) and a speciﬁcity of 86% over
all patients. With respect to the method, conclusions on
sensitivity of choline PET/CT cannot be given.
5. Conclusions
Especially patients with minimal LNM seem to beneﬁt from
the secondary removal of LNM in prostate cancer. The here
observed lasting, complete PSA remissions after secondary
resection of single LNM appear to have a feasible therapeutic
beneﬁt without adjuvant therapy. For this purpose, the
[11C]choline or [18F]ﬂuoroethylcholine PET/CT is, despite
its limitations, currently the most reliable routinely available
diagnostic tool. Whether the secondary resection of LNM
has an inﬂuence on the course of disease or could even
be curative must be demonstrated in further studies in
consideration of more patients and a long-term followup.
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